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Purpose: To identify baseline optical coherence tomography morphologic character-
istics predicting the visual response to anti-vascular endothelial growth factor therapy in 
diabetic macular edema.
Methods: Sixty-seven patients with diabetic macular edema completed a prospective,
observational study (NCT01947881-CHARTRES). All patients received monthly intravitreal
injections of Lucentis for 3 months followed by PRN treatment and underwent best-
corrected visual acuity measurements and spectral domain optical coherence tomography
at Baseline, Months 1, 2, 3, and 6. Visual treatment response was characterized as good
($10 letters), moderate (5–10 letters), and poor (,5 or letters loss). Spectral domain optical
coherence tomography images were graded before and after treatment by a certiﬁed Read-
ing Center.
Results: One month after loading dose, 26 patients (38.80%) were identiﬁed as good
responders, 19 (28.35%) as Moderate and 22 (32.83%) as poor responders. There were no
signiﬁcant best-corrected visual acuity and central retinal thickness differences at baseline
(P = 0.176; P = 0.573, respectively). Ellipsoid zone disruption and disorganization of retinal
inner layers were good predictors for treatment response, representing a signiﬁcant risk for
poor visual recovery to anti-vascular endothelial growth factor therapy (odds ratio = 10.96;
P , 0.001 for ellipsoid zone disruption and odds ratio = 7.05; P = 0.034 for disorganization
of retinal inner layers).
Conclusion: Damage of ellipsoid zone, higher values of disorganization of retinal inner
layers, and central retinal thickness decrease are good predictors of best-corrected visual
acuity response to anti-vascular endothelial growth factor therapy.
Diabetic macular edema (DME) is the major causeof visual acuity impairment in patients with dia-
betic retinopathy (DR).1 Vascular endothelial growth
factors (VEGFs) play an important role in the altera-
tions of vascular permeability and development of
DME. It interferes with the “tight junctions” of the
endothelium of the retinal vessels leading to a breakdown
of the BRB and consequent leakage to the retinal tissue.2
Based on this concept, the administration of intravitreal
(IVT) anti-VEGFs in DME has been widely demon-
strated to be efﬁcient in macular thickness improvement
and consequent increase of best-corrected visual
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acuity (BCVA),3,4 although these results may not be
permanent and multiple injections may be required
to maintain treatment efﬁcacy. Furthermore, in some
cases, the resolution of DME is not followed by
recovery of visual function. According to Elman
et al,5 after 24 months of treatment with ranibizumab
and deferred laser, 49% of the subjects had a BCVA
gain $10 letters (good responders), 22% had
a BCVA gain between 5 and 10 letters (responders),
and 29% had a BCVA gain ,5 letters or a decrease
in BCVA (poor responders). Massin et al6 and
Mitchell et al7 refer that after 12 months of treatment
with ranibizumab in monotherapy, 40% to 60% of
the subjects had a BCVA gain $10 letters, 30% had
a BCVA gain between 5 and 10 letters, and 10% to
30% had a BCVA gain ,5 letters or a decrease in
BCVA. Moreover, Gonzalez et al,8 in a post hoc
analysis of Diabetic Retinopathy Clinical Research
Network’s Protocol I data, showed that the mean
change in BCVA from Month 3 to Month 12 is lower
than 5 letters indicating that the response to the load-
ing dose (3 initial monthly injections) seems to
determine the ﬁnal visual recovery at 1 and 3 years.
It is, therefore, of major importance to characterize
the baseline features that may identify the different
visual outcomes observed in different eyes after the
initial three monthly injections of anti-VEGF in DME
and if any of these characteristics can predict poor
response to treatment.
Damage in the inner/outer segments of the photo-
receptor layer (IS/OS), currently termed as ellipsoid
zone (EZ),9 or in the retinal pigment epithelium have
been reported to predict the visual response to treat-
ment with anti-VEGF injections, as well as the
extent of disorganization of the retinal inner layers
(DRIL).10–12 However, most of these studies were
performed retrospectively or in patients previously
treated with IVT corticosteroids or anti-angiogenic
drugs.
In this study, we sought to analyze and quantify
the DME morphologic features that could correlate
with BCVA response in the initial stage of anti-
VEGF treatment response (after the loading dose)
and up to 6 months, in a prospective study of well-
characterized naive patients with DME that has
clinical indication for ranibizumab treatment. Using
a detailed grading of spectral domain optical coher-
ence tomography (SD-OCT) images, we assessed
not only the central retinal thickness (CRT) response
to therapy but also the baseline morphologic char-
acteristics of outer and inner retinal layers, as well as
size and location of cystoid spaces, and their
relationship with visual acuity outcomes.
Methods
Study Design
A prospective, exploratory, and observational
study (NCT01947881-CHARTRES) was conducted
in diabetic Type 2 patients receiving the same
interventional treatment after clinical practice guide-
lines. The study adhered to the tenets of the
Declaration of Helsinki and was approved by the
Institutional review board and ethics committee of
AIBILI, Coimbra, Portugal. Written informed con-
sent was obtained from all study patients. Patients
were treated and followed according to the standard
practice for DME treatment with ranibizumab IVT
injections as described in the Summary of Product
Characteristics (SmPC): Loading dose of three
monthly injections followed by PRN regimen.
Sample Calculation
The previously mentioned authors5–7 showed that it
is expected to have 40% to 60% of good responders,
20% to 30% of responders, and 20% to 30% of poor
responders after 12 and 24 months of IVT treatment
with ranibizumab for DME. Therefore, focusing on the
initial 3 months of treatment (the loading dose of three
monthly IVT injections), and taking into account that
at least one of the three groups may only represent
20% of the sample, the inclusion of 70 subjects was
considered appropriate to cover the extreme situation
of 42 good responders (60%), 14 responders (20%),
and 14 poor responders (20%).
Study Participants
Naive patients with indication for treatment with
ranibizumab injections for DME in the investigator’s
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opinion and fulﬁlling the following inclusion criteria
1) Type 2 Diabetes Mellitus; 2) center-involved DME,
conﬁrmed by OCT and deﬁned as a baseline SD-OCT
central subﬁeld retinal thickness $300 mm13,14; 3)
visual impairment due to DME with BCVA $ 20/
160 and # 20/40 ($39 letters and #73 letters); 4)
glycated hemoglobin (HbA1C) #12% at screening
visit. Exclusion criteria: 1) presence of proliferative
DR; 2) previous laser photocoagulation (panretinal or
focal) in the study eye within 6 months before study
inclusion; 3) previous treatments with IVT injections
of triancinolone or anti-VEGF drugs in the study eye;
4) previous vitrectomy surgery; 6) other chorioretinal
diseases such as central serous chorioretinopathy,
high myopia, chorioretinitis, or any other fundus dis-
ease associated with morphologic or functional
changes.
Study Procedures
All included patients performed an initial visit (V1)
with the following procedures: clinical history (med-
ical history, demographics, and concomitant medica-
tions); vital signs, metabolic analysis; biomicroscopy;
intraocular pressure with Goldmann tonometry; oph-
thalmoscopy; BCVA (using ETDRS method); color
fundus photography—FP (7 ETDRS ﬁelds); SD-OCT
(HD-OCT Cirrus, Zeiss Meditec); and ﬂuorescein
angiography–FA (Topcon TRC 50DXTM).
After baseline visit (V1), all patients were treated
with three monthly IVT injections of anti-VEGF
ranibizumab during 3 months (loading dose—V2, V3
and V4) and monitored at each visit before injection
with BCVA and OCT measurements. One month after
the last injection of the loading dose period (V5), i.e., 3
months after the ﬁrst injection, BCVA, OCT, CFP, and
FA procedures were repeated, and patients received
more monthly injections after a PRN regimen if the
central retinal thickness remained $300 mm. Patients
were monitored monthly with BCVA, and OCT exami-
nations and the ﬁnal visit (V6) was performed 6 months
after the ﬁrst injection. Best-corrected visual acuity,
OCT, CFP, and FA were performed as well. Optical
coherence tomography, CFP, and FA images were
graded by certiﬁed graders in a reading center—Coim-
bra Ophthalmology Reading Centre (CORC). Quality
control of CFP and FA grading was ensured by double
grading in 8% of all cases with an observed agreement
of 93.8% between graders.
Optical Coherence Tomography Acquisition
and Grading
A Macular Cube 512 · 128 scan and 2 macular 5
HD lines (at 180° and 90°) were acquired in all
patients using HD-OCT Cirrus 5000 (Zeiss Medi-
tec, Dublin). A detailed OCT double grading was
done in all visits by two CORC independent
graders. The observed agreement between the 2
graders was 93.6%. All disagreement cases were
resolved by mutual agreement. Central retinal thick-
ness, perifoveal, and parafoveal retinal thicknesses
were quantiﬁed using Macular Cube maps. Diabetic
macular edema was classiﬁed as diffuse or cystoid
(cystoid macular edema);15 cystoid macular edema
was also classiﬁed according the location of cystoid
spaces in the retinal layers (inner, outer, or overall
cystoid spaces) and severity (mild, moderate, or
severe cystoid spaces),16 The integrity of both inner
and outer retinal layers was also accessed (Figure 1).
Disorganization of the retinal inner layers (DRIL)
was deﬁned as the horizontal extent in microns for
which any boundaries between the ganglion cell–
inner plexiform layer complex, inner nuclear layer,
and outer plexiform layer could not be identiﬁed.11
The DRIL extent was measured using the equipment
software calliper in each of the ﬁve horizontal HD
B-scans, and these measurements were averaged
across ﬁve scans to derive a global DRIL area for
each eye at baseline. Disruption of external retinal
membrane (ELM), EZ and retinal pigment epithe-
lium complex were deﬁned as the horizontal extent
with loss of the hyperreﬂective signal that charac-
terizes each layer.17 The disruption of these layers
was also measured in the central 1 mm of the ﬁve
consecutive horizontal scans of ﬁve HD Line
protocol. Presence of neurosensorial serous detach-
ment, vitreo-macular traction, and epiretinal mem-
brane was also analyzed.
Data Analysis
One month after the loading dose, at Visit 5,
patients were categorized according to their BCVA
evolution from baseline and were stratiﬁed in three
treatment response groups: good responders ($10
ETDRS letters gained), moderate responders ($5
& ,10 ETDRS letters gained) or poor responders
(,5 ETDRS letters gained or loss of visual acuity).
Morphologic SD-OCT characteristics were com-
pared between treatment response groups by univar-
iate analysis performed with analysis of variance or
Kruskal–Wallis test and Fisher’s exact test. Sub-
sequently, multinomial logistic regression was per-
formed to identify possible treatment response
predictors. The multinomial logistic regression
generates an odds ratio (OR) for each category of
the dependent variable in relation to the reference
category.
The OR value includes the conﬁdence interval (CI
95%) allowing estimating the degree of accuracy.
To analyze associations between variables, Spear-
man’s correlation coefﬁcient and the respective sta-
tistical signiﬁcance were computed. A receiver
operating characteristic (ROC) analysis was per-
formed to identify the best predictors for a more
than ﬁve ETDRS letters improvement in BCVA.
All tests were two-sided and signiﬁcance was set
at 0.05. Statistical analysis was performed with Sta-
ta 12.1 SE (College Station, TX: StataCorp LP).
Results
A total of 71 patients were included in this study,
and 67 were considered for analysis. Four patients
(5.6%) discontinued the study, 2 voluntarily and 2
because of health complications unrelated to the
study (Figure 2).
Response to Anti-Vascular Endothelial Growth
Factor Treatment According to Final
Best-Corrected Visual Acuity
According to BCVA changes from baseline to Visit
5 (after three monthly injections of ranibizumab), 26
patients (38.81%) were considered good responders,
19 patients (28.35%) were considered moderate res-
ponders, and 22 patients (32.84%) were considered
poor responders.
Baseline Characteristics of Study Patients by
Treatment Response
Baseline characteristics (demographics, vital
signs, metabolic factors, diabetes duration, BCVA,
CRT, and ETDRS DR level) for all study popula-
tion, and by treatment response, are summarized in
Table 1. No signiﬁcant differences were found at
baseline between treatment response groups, even
after using age and diabetes duration as adjusting
factors.
Central Retinal Thickness Decrease as a Predictor
for Best-Corrected Visual Acuity
Treatment Response
Despite no signiﬁcant CRT differences between
groups at baseline, a higher and signiﬁcant CRT
decrease was found in the treatment groups with better
response at Visit 5 (1 month after loading dose) and
Visit 6 (6 months after initiating treatment), respec-
tively (P , 0.001) (Figure 3).
On a ROC analysis, CRT decrease 1 month after the
ﬁrst injection is not a statistically signiﬁcant predictor
Fig. 2. Flow chart of the study.
Fig. 1. Representative images
of the presence and extension of
DRIL and disruption of EZ and
ELM layers, measured in the 1-
mm central area (white box):
(A) Normal retinal layers
without disruption; (B) Severe
DRIL–retina inner layers
boundaries cannot be identiﬁed
in almost half of the 1-mm
central area (white circle and
white arrow); (C) Severe ELM
disruption showed by absence of
reﬂectivity in the ELM layer
(white arrow); (D) Severe EZ
disruption showed by the pres-
ence of several areas with no
hyperreﬂective signal (white
arrows).
for treatment response. However, using a threshold of
8.7% for CRT decrease, we were able to distinguish
73.3% of patients who recovered more than 5 BCVA
letters after 3 monthly injections despite a high per-
centage of false negatives (sensitivity 73.3%, speciﬁcity
50.0%, ROC AUC 0.581) (Figure 4).
Baseline Optical Coherence Tomography
Morphologic Features by Treatment Best-
Corrected Visual Acuity Response
As described above, baseline morphologic features of
DME were analyzed on OCT, as well as the degree of
disruption and disorganization of inner and outer retinal
Table 1. Baseline Characteristics of Patients
Study
Population
(n = 67)
Good
Responders
(n = 26)
Moderate
Responders
(n = 19)
Poor
Responders
(n = 22) P
Demographics
Age, mean ± SD, years 64.4 ± 10.3 64.9 ± 7.5 60.5 ± 15.7 67.2 ± 5.4 0.106
Females, n (%) 26 (38.8) 7 (26.9) 6 (31.6) 13 (59.1) 0.056
Vital signs
Heart rate, mean ± SD, bpm 73.5 ± 10.6 74.3 ± 9.9 74.1 ± 12.2 72.0 ± 10.1 0.702
Systolic blood pressure,
mean ± SD, mmHg
142.5 ± 10.3 141.9 ± 9.4 139.4 ± 10.5 145.7 ± 10.6 0.177
Diastolic blood pressure,
mean ± SD, mmHg
72.6 ± 9.0 72.7 ± 9.5 74.1 ± 8.5 71.3 ± 9.0 0.608
Metabolic factors
HbA1C, mean ± SD, % 7.8 ± 1.5 7.9 ± 1.7 8.1 ± 1.2 7.5 ± 1.5 0.385
Total cholesterol, mean ±
SD, mg/dL
189.7 ± 50.9 191.8 ± 42.3 197.8 ± 69.5 179.7 ± 40.7 0.701
HDL cholesterol, mean ±
SD, mg/dL
47.4 ± 10.8 48.2 ± 11.7 46.5 ± 11.6 47.2 ± 9.3 0.586
LDL cholesterol, mean ±
SD, mg/dL
127.1 ± 39.1 129.0 ± 35.8 134.7 ± 51.6 117.9 ± 28.7 0.542
Triglycerides, mean ± SD,
mg/dL
155.1 ± 92.2 155.5 ± 76.7 163.5 ± 135.8 146.9 ± 106.1 0.682
Disease characteristics
Diabetes duration, mean ±
SD, years
18.1 ± 7.7 18.1 ± 7.6 15.4 ± 5.7 20.5 ± 8.8 0.333
DME duration, median
(IQR), months
7.94 ± 23.62 7.81 ± 28.57 6.47 ± 15.81 9.36 ± 23.74 0.744
CRT, mean ± SD, mm 427 ± 107 421 ± 101 463 ± 144 404 ± 64 0.573
BCVA, mean ± SD, letters 63.4 ± 9.2 63.6 ± 8.5 65.7 ± 9.0 61.3 ± 10.0 0.176
Snellen equivalent 20/63 20/50 20/50 20/63
DR level (ETDRS scale), n (%)
35 (C–F) 48 (71.6) 17 (65.4) 11 (57.9) 20 (90.9) 0.062
53 (A–B) 14 (20.9) 6 (23.1) 7 (36.8) 1 (4.6)
57 (A–D) 5 (7.5) 3 (11.5) 1 (5.3) 1 (4.6)
HbA1C, glycated hemoglobin; HDL, high-density liprotein; LDL, low-density liprotein; P, P value; Age and diabetes duration were
adjusted in this analysis.
Fig. 3. Decrease of retinal
thickness by treatment response
from Baseline to Month 1 (after
ﬁrst injection), Month 2 (after
second injection), Month 3
(after third injection), and
Month 6.
layers to evaluate the possibility of predicting different
treatment responses. Signiﬁcant differences were found
among treatment response groups regarding DRIL area
(P = 0.021) and EZ and ELM disruption area (P =
0.006 and P = 0.003, respectively), at baseline. Like-
wise, cystoid spaces severity seems also to be associ-
ated with a poor response to anti-VEGF treatment. Poor
responders group have higher percentage of moderate
cystoid spaces (57.14%), whereas good responders
group showed higher percentage of mild cystoid spaces
(23.08%). However, these differences were not statisti-
cally signiﬁcant (P = 0.252) (Table 2).
Poor responders presented, at baseline, a greater
extent of EZ and ELM disruption (P = 0.003 and
0.006, respectively). Extension of DRIL area was also
signiﬁcantly higher in this group (P = 0.021) (Figure 5).
Moreover, a correlation was found between EZ and
ELM disruption area and DRIL area with the treatment
response. The presence of EZ disruption was the
morphologic characteristic with a stronger relation to
a poor response to treatment (Table 3).
Optical Coherence Tomography Predictors for
Treatment Best-Corrected Visual Acuity Response
To identify the best OCT morphologic predictors
for an improvement of more than 5 letters in
BCVA after treatment, a ROC analysis was
Fig. 4. ROC analysis for CRT
decrease as a threshold for
BCVA improvement.
Table 2. Baseline OCT Morphologic Features of DME for the Study Population and by Treatment Response Group
Study
Population
(n = 67)
Good
Responders
(n = 26)
Moderate
Responders
(n = 19)
Poor
Responders
(n = 22) P
OCT morphologic features, n (%)
Diffuse macular edema 58 (86.57) 22 (84.62) 17 (89.47) 19 (86.36) 0.999
Cystoid macular edema 67 (100) 26 (100) 19 (100) 22 (100) —
Outer cystoid spaces 64 (96.97) 25 (96.15) 18 (94.74) 21 (100) 0.745
Inner cystoid spaces 63 (95.45) 25 (96.15) 18 (94.74) 20 (95.24) 0.999
Overall cystoid spaces 20 (30.3) 7 (26.92) 9 (47.37) 4 (19.05) 0.159
Severity of cystoid spaces, n (%)
Mild 14 (21.21) 6 (23.08) 5 (26.32) 3 (14.29) 0.252
Moderate 31 (46.97) 14 (53.85) 5 (26.32) 12 (57.14)
Severe 21 (31.82) 6 (23.08) 9 (47.37) 6 (28.57)
Cystoid spaces size, n (%)
Small (,250 mm) 6 (9.09) 4 (15.38) 1 (5.25) 1 (4.76) 0.107
Medium ($250 & ,500 mm) 39 (59.09) 12 (46.15) 10 (52.63) 17 (80.95)
Large: $500 mm 21 (31.82) 10 (38.46) 8 (42.11) 3 (14.29)
Disruption of retinal layers, mm2
DRIL, mean ± SD 367.8 ± 211.0 278.6 ± 191.7 404.4 ± 158.9 441.6 ± 240.5 0.021
EZ, mean ± SD 314.7 ± 249.2 196.1 ± 201.2 327.3 ± 219.1 444.0 ± 266.2 0.003
ELM, mean ± SD 103.4 ± 158.8 30.2 ± 64.7 135.8 ± 177.9 161.9 ± 189.6 0.006
RPE, mean ± SD 31.2 ± 74.2 14.2 ± 57.6 16.4 ± 46.0 63.9 ± 99.2 0.148
Other OCT features, n (%)
NSD 22 (32.84) 6 (23.08) 7 (36.84) 9 (40.91) 0.394
Epiretinal membrane 22 (32.84) 8 (30.77) 4 (21.05) 10 (45.45) 0.263
Vitreo-retinal traction 3 (4.48) 1 (3.85) 2 (10.53) 0 0.224
ELM, external limiting membrane; NSD, neurosensorial serous detachment; P, P value (values in bold are signiﬁcant for p,0.05); RPE,
retina pigment epithelium.
performed (Table 4), showing that the best
predictor for this visual improvement was the EZ
disruption area (ROC AUC 0.71-sensitivity 59%,
speciﬁcity 80%).
The predictive value of OCT morphologic features to
treatment response after the loading dose was analyzed
with univariate multinomial logistic regression. Then,
multivariate multinomial logistic regression was per-
formed with the following parameters: EZ disruption
area and DRIL area; because these two variables
showed statistically signiﬁcant differences between
good responders and poor responders in the univariate
logistic analysis. Being the primary treatment outcomes,
BCVA and CRT were also analyzed (Table 5).
Ellipsoid zone disruption area seems to have an
important contribution to a poor functional outcome to
anti-VEGF treatment, with an OR of 10.96 (CI = 2.94–
40.8; P , 0.001) for poor responders versus good
responders, which means that the higher the EZ dis-
ruption area, the worst is expected to be the functional
treatment recovery. Disorganization of retinal inner
layer area seems also to be a risk factor for BCVA
response to treatment with an OR of 7.05 (CI = 1.16–
42.89; P = 0.034) for poor responders versus good
responders. These results are similar at Month 6
(V6), with an OR of 7.86 (CI = 2.10–29.43; P =
0.002) for EZ and an OR of 8.05 (CI = 1.20–54.01;
P = 0.032) for DRIL.
A subanalysis was performed excluding patients
who received laser therapy 6 months before inclu-
sion (32.8%) to evaluate the possible impact of this
treatment in the present biomarkers. No signiﬁcant
changes were found and DRIL and EZ remained the
major predictors of poor treatment response (results
not shown).
Discussion
Regular IVT treatment with ranibizumab in pa-
tients with DME decreases CRT and improves
BCVA.7,18 In this study, we prospectively observed
67 patient eyes with naive DME after initiating a load-
ing dose of three monthly IVT ranibizumab injections
followed by PRN treatment for up to 6 months. A
mean CRT decrease of 107.93 mm (225%) was ob-
tained immediately after the loading dose (three
monthly injections), with a signiﬁcant recovery of
BCVA (+6.78 letters; P , 0.001). These results are
in accordance with other clinical trials such as
RESTORE, RISE, and RIDE,7,18 where signiﬁcant
CRT decreases and BCVA increases were achieved
after the same regimen of ranibizumab therapy.
Although CRT is widely used to evaluate and
follow eyes with DME, it has been shown to be only
moderately correlated with BCVA outcomes.19 The
available clinical trial data have shown that only
50% to 60% of eyes treated with anti-VEGF for
DME respond with complete retinal thickening reso-
lution or have improvement of VA to 20/20 or better.20
In our study, we analyzed the potential role of CRT
decrease after the ﬁrst injection as a predictor for
BCVA. Central retinal thickness decrease does not
reach statistical signiﬁcance as a predictor for treat-
ment response, but a threshold of CRT decrease of
8.7% immediately after the ﬁrst anti-VEGF injection
(at 1 month) was able to distinguish 73.3% of patients
who recovered more than 5 BCVA letters at 3 months,
with a modest speciﬁcity. Larger sample size may, in
the future, help to clarify this ﬁnding. It is noteworthy
Fig. 5. Disruption of retinal inner layers (DRIL) area and disruption of
EZ and external limiting membrane (ELM) retinal layers by treatment
response group.
Table 3. Correlation Between Retinal Layers Disruption
and BCVA Treatment Response
Correlation P
EZ disruption
area
rs = 20.56; CI = 20.70 to
20.36
,0.001
ELM disruption
area
rs = 20.52; CI = 20.67 to
20.32
,0.001
DRIL area rs = 20.39; CI = 20.58 to
20.17
0.001
P, P value; rs, Spearman correlation coefﬁcient.
Table 4. Area Under the Curve and Sensitivity and
Speciﬁcity for the DRIL Area and EZ and ELM Disruption
Areas
ROC AUC
Sensitivity
at 80%
Speciﬁcity
DRIL area 0.65 (CI 95% = 0.50–0.81) 55
EZ disruption
area
0.71 (CI 95% = 0.56–0.85) 59
ELM disruption
area
0.64 (CI 95% = 0.50–0.78) 45
CRT and RPE disruption area did not show acceptable
accuracy to discriminate poor responders.
AUC, area under the curve; RPE, retinal pigment epithelium.
that other studies21 have based their retreatment crite-
ria in a similar percentage of CRT decrease (10%
between visits).
However, whereas some patients have an excellent
visual outcome after treatment, some others maintain
a substantial visual disability. Robust predictive bio-
markers for treatment response in eyes with DME are
still lacking despite the large number of studies and
reports dedicated to this subject.
A number of studies10,22,23 have suggested modest
associations between OCT parameters, such as pres-
ence of intraretinal cysts, hyperreﬂective foci, subreti-
nal ﬂuid, disruption of ELM, and photoreceptors layer
(EZ), with BCVA in eyes with DME, but these corre-
lations have not been strong enough to predict visual
acuity reliably and most of the reported studies were
conducted retrospectively in mixed treatment cohorts.
Other studies11,24 have identiﬁed DRIL on OCT as
a parameter indicating highly associated with current
and future vision in eyes with DME. These authors
found that DRIL affecting 50% of the 1-mm central
retinal zone was the only parameter consistently asso-
ciated with worse BCVA in eyes with current DME
and resolved DME after treatment. They also found
that increasing of DRIL in the course of the treatment
was associated with reduction in BCVA. But again,
data from these studies were obtained retrospectively,
as part of routine clinical care rather than part of
a research protocol and included eyes that underwent
different DME treatments before and during the study
follow-up and with different DME durations.
In this prospective study, we were able to conﬁrm
that presence and extent of DRIL before treatment are
correlated with BCVA outcomes to anti-VEGF ther-
apy after the loading dose and, most important, the
presence of these morphologic changes seems to be
a good predictor of treatment response, representing
a risk of almost 8 times higher for poor visual recovery
than patients without DRIL. The mechanisms by
which DRIL affects BCVA are yet to be determined,
although it likely to represent signs of anatomical
interruption in the visual transmission pathway from
the photoreceptors to the ganglion cells.11,25
However, Maheshwary et al17 found a statically sig-
niﬁcant correlation between the percentage of photo-
receptors IS/OS disruption and visual acuity, which
means that EZ disruption may be another signiﬁcant
predictor of VA in patients with DME. However, pa-
tients who gained normal vision after treatment were
excluded from the analysis, which can compromise the
predictive value of this feature. In our study, a signif-
icantly higher percentage of EZ and ELM disruption
was found at baseline in the poor responders group
compared with good responders, and a moderate
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correlation was found between the presence of these
features and the response to treatment. Our data have
also showed that more EZ disruption at baseline rep-
resents a higher risk for a poor visual recovery (OR:
10.96; P , 0.001), when comparing to the presence of
DRIL (OR: 7.05; P = 0.001).
Macular cystoid spaces have been proposed as
another indicator of retinal damage. Raafay et al10
found that their presence predicted a reduction in
BCVA letter score and that the presence of large cys-
toid spaces seems to be more disruptive than small
ones. Likewise, in our work, cystoid spaces severity
seems also to be a predictor of poor response to anti-
VEGF treatment.
Our study validates the importance of determination
of morphologic patterns on SD-OCT and shows that
the integrity of both inner (DRIL) and outer retinal
layers (EZ and ELM) can be good predictive bio-
markers of future BCVA in patients with DME
undergoing anti-VEGF therapy.
This study is considered particularly relevant
because it was conducted prospectively, in treatment
naive patients who were submitted to the same
regimen of ranibizumab treatment and followed up
with several examinations before, during, and after
therapy. Diabetes duration and DME duration were
not signiﬁcantly different between treatment
response groups (P = 0.333 and P = 0.444, respec-
tively) and most of the patients (70%) presented
a DR severity ETDRS level of 35 at baseline which
means that it is a population of relatively mild-to-
moderate DR and thus, ideal to study such detailed
morphologic retinal changes as DRIL, EZ, and ELM
disruption with accuracy. It also means that these
changes are already present in early stages of DR
and, therefore, could provide a signiﬁcant contribu-
tion to counseling, management, and treatment of
diabetic macular edema.
It is noteworthy that in our study, previous laser
treatment performed 6 months before inclusion did not
show any signiﬁcant inﬂuence in the characterization
of the OCT nor any identiﬁable impact in treatment
response to anti-VEGF treatment.
Study limitations include the fact that the study
deals with a relatively small population, although
chosen according to sample size calculation, and the
chosen focus on the initial stage (loading dose) of
IVT anti-VEGF, not allowing the evaluation of long-
term effects of the anti-VEGF therapy. Larger and
longer prospective studies are needed to evaluate
these aspects. However, despite the focus on initial
treatment response (after the loading dose), there
were no signiﬁcant changes in the predictive value
of these biomarkers for the BCVA response at 6
months, even after PRN regimen, an observation
which is in accordance with previously described
studies.5–7
In conclusion, SD-OCT provides useful information
for determining visual prognoses and outcomes in
DME treatment. In naive cases of DME, DRIL, and
specially EZ are conﬁrmed as useful structural markers
to evaluate retinal tissue integrity and are closely
associated with ﬁnal BCVA after treatment.
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